Risk of serious medical events in patients with depression treated with electroconvulsive therapy: a propensity score-matched, retrospective cohort study
- PMID: 34265274
- DOI: 10.1016/S2215-0366(21)00168-1
Risk of serious medical events in patients with depression treated with electroconvulsive therapy: a propensity score-matched, retrospective cohort study
Abstract
Background: Previous studies examining the risk of medical complications from electroconvulsive therapy have been confounded and this might contribute to its underuse. This study aimed to compare the risk of serious medical events, defined as those resulting in hospitalisation or death, among patients with depression who received electroconvulsive therapy versus patients who did not receive electroconvulsive therapy.
Methods: This was a propensity score-matched, retrospective cohort study using linked population-based administrative health data for adults admitted to designated psychiatric facilities in Ontario, Canada, for more than 3 days with depression between April 1, 2007, to Feb 28, 2017. Electroconvulsive therapy exposure was defined as one or more physician billing procedure codes during hospitalisation. The unit of analysis was individual admissions and propensity score matching was used to match each exposed admission to an unexposed admission to estimate the average treatment effect of electroconvulsive therapy among those treated. The primary outcome was serious medical events, a composite of hospitalisation for medical (ie, non-psychiatric) reasons or non-suicide death within 30 days from electroconvulsive therapy exposure or matched date in the unexposed group. Effect modification was examined using tests of interaction for three clinically relevant prespecified subgroups (sex, presence of psychotic symptoms, and illness polarity). Secondary outcomes were medical hospitalisation and non-suicide death separately, suicide death, and specific serious medical events.
Findings: In propensity score matched analyses, there were 10 016 psychiatric hospitalisation records (6628 women, 3388 men) with mean age 56·6 years (SD 16·3) and no ethnicity data available. 65 818 admissions were eligible for matching and 5008 were matched (1:1) in each exposure group. In the propensity score matched cohort, the incidence of serious medical events was 0·25 per person-year in the exposed group and 0·33 per person-year in the unexposed group (cause-specific hazard ratio 0·78 [95% CI 0·61-1·00]). Suicide death as a competing risk did not alter this finding. The risk of suicide death was significantly lower in the exposed (≤5 of 5008 admissions) versus the unexposed group (11 [0·2%] of 5008 admissions; p<0·03). Bipolar depression, compared with unipolar depression, was associated with a greater reduction in the risk of serious medical events with electroconvulsive therapy. Electroconvulsive therapy was not associated with medical hospitalisation or non-suicide death separately, nor with any specific serious medical event.
Interpretation: Among individuals hospitalised with depression, we found no evidence for a clinically significant increased risk for serious medical events with exposure to electroconvulsive therapy, and the risk of suicide was found to be significantly reduced, suggesting the benefits of electroconvulsive therapy for depression outcomes might outweigh its risks in this population.
Funding: Norris Scholars Award, Department of Psychiatry, University of Toronto; the Canadian Institutes for Health Research.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests TSK is supported by the Canadian Institute for Health Research Fellowship Award. DMB is supported by the Canadian Institutes of Health Research, the US National Institutes of Health, Weston Brain Institute, Brain Canada, and the Temerty Family through the Centre for Addiction and Mental Health Foundation and the Campbell Research Institute. DMB also received research support and in-kind equipment support for an investigator-initiated study from Brainsway, is the site principal investigator for three sponsor-initiated studies for Brainsway, received in-kind equipment support from Magventure for an investigator-initiated study, received medication supplies for an investigator-initiated trial from Indivior, and has participated in an advisory board for Janssen. TG is supported by a Canada Research Chair in Drug Policy Research and Evaluation and has received grant support for a research programme outside of the present manuscript from the Ontario Ministry of Health. DNW is supported by a New Investigator Award from the Canadian Institutes of Health Research, an Excellence in Research Award from the Department of Anesthesia at the University of Toronto, and the Endowed Chair in Translational Anesthesiology Research at St Michael's Hospital and University of Toronto. SNV is supported by Women's College Hospital, the University of Toronto Department of Psychiatry, and by a New Investigator Award from the Canadian Institutes for Health Research. SNV also reports royalties from UpToDate for authorship of materials related to antidepressants and pregnancy. RS declares no competing interests.
Comment in
-
Morbidity and mortality associated with electroconvulsive therapy: can we control for confounding?Lancet Psychiatry. 2021 Aug;8(8):643-644. doi: 10.1016/S2215-0366(21)00238-8. Epub 2021 Jul 12. Lancet Psychiatry. 2021. PMID: 34265273 No abstract available.
-
Time to acknowledge good electroconvulsive therapy research.Lancet Psychiatry. 2021 Dec;8(12):1032-1033. doi: 10.1016/S2215-0366(21)00352-7. Lancet Psychiatry. 2021. PMID: 34801120 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous